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Dendritic cell (DC)-mediated cross-presentation of
exogenous antigens acquired in the periphery is crit-
ical for the initiation of CD8+ T cell responses. Several
DC subsets are described in human tissues but
migratory cross-presenting DCs have not been iso-
lated, despite their potential importance in immunity
to pathogens, vaccines, and tumors and tolerance to
self. Here, we identified a CD141hi DC present in
human interstitial dermis, liver, and lung that was
distinct from the majority of CD1c+ and CD14+ tissue
DCs and superior at cross-presenting soluble anti-
gens. Cutaneous CD141hi DCs were closely related
to blood CD141+ DCs, and migratory counterparts
were found among skin-draining lymph node DCs.
Comparative transcriptomic analysis with mouse
showed tissue DC subsets to be conserved between
species and permitted close alignment of human
and mouse DC subsets. These studies inform the
rational design of targeted immunotherapies and
facilitate translation of mouse functional DC biology
to the human setting.
INTRODUCTION
Dendritic cells (DCs) are a heterogeneous population of rare
leukocytes found in virtually all tissues, where they form a
network of antigen-sensing and -presenting cells (Steinman,
2007). The main role of DCs is to induce specific immunity60 Immunity 37, 60–73, July 27, 2012 ª2012 Elsevier Inc.against invading pathogens while maintaining tolerance to self-
antigens. DC-mediated cross-presentation of exogenous anti-
gens to CD8+ T cells is critical for the priming and activation
of cellular immunity to viruses, tumors, and vaccines and to
promote tolerance through the deletion of self-reactive CD8+
T cells (Kurts et al., 2010).
By virtue of their location, migratory tissue DCs play a central
role in the induction of immunity (Banchereau and Steinman,
1998; Allenspach et al., 2008). Cross-presenting migratory DCs
are functionally and anatomically specialized to acquire exoge-
nous antigen in the tissues and initiate CD8+ T cell responses
(Helft et al., 2010; del Rio et al., 2010). Although cross-presenting
capacity is also found in lymph node (LN)-resident DCs and
may augment antigen presentation by migratory DCs (Shortman
and Heath, 2010), the latter are obligatory for efficient T cell
priming (Allenspach et al., 2008).
Studies inmice have identified two lineages ofmigratory tissue
DCs defined by differential expression of CD103 and CD11b.
CD103+ DCs cross-present antigen to CD8+ T cells more effec-
tively than do CD11b+ DCs in a number of viral infection, tumor,
and self-antigen models (Helft et al., 2010; del Rio et al., 2010).
Although these DCs play a critical role in immunity, no population
with this activity has ever been isolated from human nonlym-
phoid organs. Human DCs of the interstitial dermis are the best
described tissue DCs and comprise two subsets delineated by
expression of CD1a and CD14 (Lenz et al., 1993; Nestle et al.,
1993; Klechevsky et al., 2008; Haniffa et al., 2009). The surface
markers bear no relation to mouse DCs and neither human DC
subset excels in cross-presentation, so a functional homolog
of the mouse CD103+ DC remains elusive (Collin et al., 2011).
Several lines of evidence indicate that CD103+ cross-present-
ing tissue DCs and CD8+ lymphoid-resident DCs together form
a distinct DC lineage. Studies of genetic factors affecting DC
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tion of IRF8, Id2, and Batf3 (Aliberti et al., 2003; Edelson et al.,
2010) and both arise from a common precursor, the pre-DC
(Ginhoux et al., 2009; Liu et al., 2009). Additional phenotypic
and functional properties are found in common between
CD103+ and CD8+ DCs including uptake of apoptotic cells via
the lectin CLEC9A (Caminschi et al., 2008; Huysamen et al.,
2008; Sancho et al., 2009), responsiveness to TLR3 stimulation
(Jelinek et al., 2011), and expression of the chemokine receptor
XCR1 (Crozat et al., 2011). The lectins DEC205 and langerin are
also expressed on DCs of this lineage in a number of different
sites (Contreras et al., 2010; Ginhoux et al., 2009).
Recent progress was made in identifying potential homologs
of mouse DC subsets by examining human blood DCs. In addi-
tion to plasmacytoid DCs (pDCs), human blood harbors two
subsets of CD11c+ myeloid DCs: a major CD1c+ (BDCA-1) pop-
ulation and a discrete CD141+ (thrombomodulin or BDCA-3)
subset (Dzionek et al., 2000; MacDonald et al., 2002; Ziegler-
Heitbrock et al., 2010). Compared with CD1c+ DCs, blood
CD141+ DCs exhibit specialized cross-presenting function and
express a number of markers associated with mouse CD8+
DCs (Jongbloed et al., 2010; Bachem et al., 2010; Crozat et al.,
2010a; Poulin et al., 2010) including NECL2 (cellular adhesion
molecule-1; CADM1) (Galibert et al., 2005) and CLEC9A (Camin-
schi et al., 2008; Huysamen et al., 2008; Sancho et al., 2009).
Cloning of XCL1 and subsequent mapping of its receptor to
a restricted set of DCs led to the discovery of XCR1 as a signature
chemokine axis of cross-presenting DCs (Dorner et al., 2009;
Crozat et al., 2010a). Together with TLR3, these markers provide
a concise functional profile of cross-presenting DCs that tran-
scends species barriers.
Although the function of human blood myeloid DCs is not
known and they have no counterparts in mouse blood, these
observations gave us further impetus to look for migratory
cross-presenting DCs in human nonlymphoid tissues and to
discover how they relate to known human tissue and blood
populations. Here we identify the human tissue cross-presenting
DC as a discrete population of CD141hiCD11clo-int DCs in the
HLA-DR+, lineage, CD14 compartment of skin, liver, and
lung. Comparison of this cell with the major population of
CD1c+ DCs, CD14+ DCs, and blood DCs allowed us to align
mouse and human DC subsets across species. The character-
ization of CD141hi DCs is likely to be fundamentally important
in learning how to manipulate immune responses to tumors,
viruses, and vaccines.
RESULTS
Identification of CD141hi DCs in Human Tissues
We have previously described a strategy to identify CD1a+ DCs,
CD14+ DCs, and macrophages in freshly digested dermis (Ha-
niffa et al., 2009). We combined this with a conventional analysis
of human blood DCs to compare phenotypically equivalent cells
from blood and tissues in parallel (Figure 1). Lineage cocktail in
FITC was used to exclude auto-fluorescent tissue macrophages
and lineage-positive cells. Antibodies to CD14 and CD16 were
put in separate channels to identify monocyte subsets, and
CD11c, CD1c, and CD141 markers were added to map tissue
DC subsets to the parameter space of blood DC analysis. Fullgating strategy and percentage of DC populations in blood and
tissues are shown in Figure S1 available online.
HLA-DR+lineage cells in all tissues comprise a CD14 and
CD14+ fraction (Figure 1A). Blood, and to a lesser extent lung
and liver, also contain CD16+ monocytes or equivalent cells.
The CD14 fraction may be further separated by CD141
and CD11c expression. In blood, typical CD141+ DCs are a
distinct population with lower CD11c expression. This popula-
tion is mirrored in skin, liver, and lung as CD141hi cells with
low-to-intermediate CD11c expression. The CD14+ fraction
contains CD11c+ cells with a variable CD141 expression but
no CD141hiCD11clo-int cells. Double-negative cells on the plot
of CD141 versus CD11c in blood correspond to CD123+ pDCs
and CD34+ progenitor cells (Figure S1). CD141loCD11clo cells
on the plot of CD141 versus CD11c in skin preparations express
high CD1a and langerin and are epidermal Langerhans cells
(LCs) (Figures 1A and S1).
The expression of CD1c, CD1a, and langerin is defined in
Figure 1B. CD141hiCD11clo-int cells have lower expression
of CD1c and are further described as ‘‘CD141hi DCs.’’ All
CD141loCD11chi cells express higher CD1c and are hereafter
referred to as ‘‘CD1c+ DCs.’’ CD1a and langerin are not found
on blood DCs but are variably expressed in the tissues on a
small fraction of CD1c+ DCs. CD141hi DCs do not express lan-
gerin and have similar HLA-DR expression levels to CD1c+
DCs (data not shown).
In order to verify this approach and to allow comparison with
previous studies on DCs migrating from human skin, we
compared freshly digested and migrated skin preparations by
gating cells according to relative expression of CD14 and
CD1c (Figure 1C). In both preparations, the CD14 fractions
include a distinct minor population of CD141hiCD11clo cells, cor-
responding to the cells identified previously. TheCD14+ fractions
contain CD11chi cells with variable to high CD141 expression but
no cells in the CD141hiCD11clo gates. To clarify that CD141hi
DCs were tissue residents and not contaminating blood cells,
we estimated their frequency relative to CD45+ mononuclear
cells. CD141hi DCs were enriched relative to CD141+ DCs in
blood in all tissues, especially the skin (Figure 1D).
From these results, we conclude that CD141hi DCs may
be identified as a discrete population of HLA-DR+lineage
CD14CD141hiCD11clo-int cells of skin, lung, and liver. Parallel
phenotypic analysis suggests that they are potentially related
to blood CD141+ DCs. Although CD14+ cells in all tissues
express CD141, they correspond to previously identified
CD14+ ‘‘interstitial-type DCs’’ of skin that do not have very
potent allostimulatory or cross-presenting capacity (Klechevsky
et al., 2008; Haniffa et al., 2009). Hereafter, we refer to these cells
as ‘‘CD14+ DCs.’’
CD141hi Tissue DCs Express Markers of Cross-
Presenting DCs
Seeking further evidence that tissue CD141hi cells were tissue
cross-presenting DCs, we characterized their expression of
signature markers such as XCR1, TLR3, CLEC9A, and CADM1.
Mindful that CD141 expression was also found on CD14+
DCs and some CD1c+ DCs, these fractions were included to
ensure that they were not also enriched for potential cross-pre-
senting DCs (Figure 2A).Immunity 37, 60–73, July 27, 2012 ª2012 Elsevier Inc. 61
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Figure 1. Identification of CD141hi DCs in Human Tissues
(A) Flow cytometry of peripheral blood, collagenase-treated whole skin, liver, andmechanically dispersed lung. Gating strategy used to identify three myeloid DC
subsets within LinHLA-DR+ fraction (yellow gate) in tissues: (1) CD14+ DCs (blue gate), (2) CD14CD11c+ DCs (green gate), and (3) CD14CD11cloCD141hi DCs
(red gate). Langerinhi epidermal LCs (purple gate) are identifiable in the skin. Representative data from 20 blood, 18 skin, 12 liver, and 8 lung donors are shown.
(B) Relative expression of CD1c, CD1a, and langerin by CD11c+ DCs (green) and CD141hi DCs (red). Representative data from four blood, skin, liver, and lung
donors are shown.
(C) Identical gating strategy as (A) to correlate CD141hi cells with established populations of skin DCs from digested dermis and spontaneously migrating DCs
from skin explants cultured for 60 hr. Representative data from seven skin donors are shown.
(D) Frequency of CD141hi cells as a percent of CD45+ mononuclear cells in skin, liver, and lung relative to peripheral blood. Composite data from six blood, skin,
liver, and lung donors are shown. *p < 0.05, Mann-Whitney U test.
See also Figure S1.
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Figure 2. CD141hi Tissue DCs Express
Markers of Cross-Presenting DCs
(A) LinHLA-DR+ cells from blood and skin were
FACS purified according to gating shown in dot
plots.
(B) RNA from FACS-purified cells in (A) was
analyzed for the expression of XCR1, TLR3,
CLEC9A, and CADM1 by qRT-PCR. Data shown
are from two blood and skin donors.
(C) DC migration from skin explants cultured
ex vivo over 24 hr in medium alone () or with
XCL1 or CCL3. Composite data from four skin
donors are shown, mean ± SEM. *p < 0.05, Mann-
Whitney U test.
(D) Relative expression of FLT3, CLEC9A,MCSFR,
and CX3CR1 by CD14+ DCs (blue), CD1c+ DCs
(green), and CD141hi DCs (red) compared to iso-
type (gray) from blood, skin, and lung. Represen-
tative data from three blood, skin, and lung donors
are shown.
(E and F) Morphology of FACS-sorted blood and
skin CD141+, CD1c+, and CD14+ DCs and mono-
cytes (E) visualized by GIEMSA staining of cyto-
spin preparations (X100) and (F) by SEM. Scale
bars represent 10 mm in (E) and 1 mm in (F).
(G) Pseudo-color (363) images of whole-mount
skin immunostained for MHC class II (HLA-DR,
HLA-DQ, and HLA-DP) (green), CD11c (blue), and
XCR1 (red). White arrows in overlay image (right
bottom) highlight the XCR1+CD11cloHLA-DR+
cells corresponding to skin CD141hi DCs. Scale
bars represent 5 mm.
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Human Migratory Cross-Presenting CD141hi DCsAs expected, XCR1, TLR3, CLEC9A, and CADM1 were upre-
gulated on blood CD141+ DCs compared with blood CD1c+
DCs and CD14+ monocytes (Figure 2B). A close correlation
was seen with CD141hi DCs whereas CD14+ DCs and both frac-
tions of CD1c+ DCs had much lower expression of all markers.
These data indicate that of the interstitial dermal subsets,
CD141hi DCs, but not other CD141+ cells, are potential cross-
presenting DCs.
To corroborate the transcription profiles, we examined the
response of dermal DC subsets to XCL1 in vitro (Figure 2C).
XCL1 significantly and selectively increased the proportion of
CD141hi DCs migrating from explanted skin over 24 hr.
CD141hi DCs also showed the highest expression of FLT3 and
CLEC9A in blood, skin, and lung, whereas CD14+ DCs ex-
pressed the most M-CSFR and CX3CR1, markers associated
with the monocyte and macrophage lineages. CD1c+ DCs
showed lower expression of FLT3 and CLEC9A and interme-Immunity 37, 6diate levels of M-CSFR and CX3CR1,
compared with CD141hi DCs (Figure 2D).
The morphology of sorted blood and
skin DCs was examined by Giemsa stain-
ing of cytospin preparations (Figure 2E)
and scanning electron microscopy (SEM)
(Figure 2F). Both CD141hi and CD1c+
DCs showed prominent membrane
ruffling compared with CD14+ DCs, which
were generally smoother. CD141hi DCs
had more numerous small lamellipodiathan did CD1c+ DCs. With four-color immunofluorescence
staining of whole-mount skin, it was possible to discern HLA-
DR+XCR1+ cells with low CD11c expression, consistent with
the phenotype of CD141hi DCs, in the apical dermis (Figure 2G).
Other HLA-DR+CD11chiXCR1 cells may be seen in the same
field, most probably representing either CD1c+ DCs or CD14+
DCs. CD141 itself could not be used as a marker to visualize
these cells directly because it is widely expressed on leukocytes
and endothelial cells.
Skin CD141hi DCs Potentially Develop from Blood
CD141+ DCs
Comparison of skin CD141hi DCs with blood CD141+ DCs
suggested a potential developmental relationship between the
blood and skin. All tissue DCs, especially CD141hi DCs, ex-
pressed an activated phenotype compared with the blood
(Figures 3A and 3B) and acquired high levels of CCR7 while0–73, July 27, 2012 ª2012 Elsevier Inc. 63
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Figure 3. Skin CD141hi DCs Potentially Develop from Blood CD141+ DCs
(A and B) Relative expression of (A) CD80, CD83, CD86, and PD-L1 and of (B) CLA and CCR7 by blood and skin CD14+ DCs (blue), CD1c+ DCs (green), and
CD141hi DCs (red) compared to isotype (gray). Representative data from three blood, skin, and lung donors are shown.
(C) Relative expression of CD80, CD83, CD86, and CCR7 (blue) to isotype control (gray) by CD1a+CD1c+ and CD1aCD1c fractions of CD141hi cells in the skin
(shown with their relative percentages). Representative data from three skin donors are shown.
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Figure 4. CD141hi DCs Migrate to Skin-
Draining Lymph Node
(A) Identification of migratory (mig) and resident
(res) DCs in mechanically dispersed dermato-
pathic LN (left) and tonsil (right).
(B) Comparison of CD141hi and CD1c+ DCs in
migratory (mig) and resident (res) fractions. Rela-
tive expression of CD1c, CD1a, and langerin by
CD1c+ DCs (green), CD141hi DCs (red), and cells
from epidermal LC gate (purple).
(C) Relative expression of CD80, CD83, CD86, and
CCR7 by migratory (tinted) and resident CD14+
DCs (blue), CD1c+ DCs (green), and CD141hi DCs
(red) compared to isotype (gray).
Representative data from four dermatopathic LNs
and four tonsils are shown.
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Human Migratory Cross-Presenting CD141hi DCsdownregulating the skin-homing molecule cutaneous lympho-
cyte antigen (CLA, also known as P-selectin glycoprotein ligand;
PSGL-1) (Figures 3A and 3B).
Careful analysis of skin CD141hi DCs shows two distinct pop-
ulations of cells with differential expression of CD1a and CD1c
(Figure 3C). A minor population of CD1aCD1c cells is present.
Although these do not express CLA and cannot be blood
CD141+ DCs per se, they have a similar immature phenotype
(Figure 3C). These data are consistent with the possibility that
blood CD141+ DCs are the precursors of immature CD141hi
DCs, before acquiring CD1a, CD1c, activation antigens, and
CCR7. To examine this possibility, we added sorted and labeled
CD141+ blood DCs to a skin preparation and observed an upre-
gulation of CD1a and CD1c in keeping with the tissue CD141hi
DC phenotype (Figure 3D). Furthermore, migrating CD141hi
DCs represented only the CD1a and CD1c mature fraction.
This is at least consistent with a precursor-progeny relationship
between blood CD141+ DCs and skin CD141hi DCs. In mouse
experiments, blood pre-DCs are not proliferating but go into
cell cycle upon entry into the tissues (Liu et al., 2009). Reminis-(D) CD1c and CD1a expression by FACS-purified, Qtracker605-labeled blood CD141+ DCs cultured in medium
migrated CD141hi cells from 60 hr skin explants cultured ex vivo (Migrants). Representative data from two bloo
donors for skin explant migration are shown.
(E) DNA content of FACS-sorted blood and skin CD14+, CD1c+, and CD141hi DCs. Right panel shows perce
Representative and composite data from four blood and five skin donors are shown, mean ± SEM. *p < 0.05,
with all other subsets.
Immunity 37, 6cent of this, we found that blood
CD141+ DCs are not cycling but 4% of
CD141hi DCs are in S, G2, or M phase
by DNA content analysis (Figure 3E).
CD141hi DCs Migrate to Skin-
Draining Lymph Nodes
CD141hi DCs migrate spontaneously
in vitro (Figures 1 and 2) and express
CCR7 (Figure 3), suggesting that they
may migrate to LNs in vivo. To test this
further we compared dermatopathic LN,
which contains a high content of migra-
tory DCs, with tonsil, a lymphoid tissue
lacking afferent lymphatics (Figure 4A).Dermatopathic LNs contained an additional CD11cloHLA-DRhi
population. Based on the comparison of these two tissues and
in keeping with the phenotype of migrating DCs in mouse LNs
(Ohl et al., 2004), we identified the CD11cloHLA-DRhi population
as tissue migratory DCs. Both LN and tonsil contained pDC and
a CD11chiHLA-DRlo population, which contain resident DCs.
Within both fractions, we found CD141hi DCs and CD1c+ DCs
but Langerhans cells, as predicted, were confined to the migra-
tory fraction. In keeping with the phenotype expected of migra-
tory cells that we had observed directly in the skin, all migratory
fractions expressed higher CD1c, CD1a, CCR7, and activation
antigens than did their resident counterparts. Taken together,
these data indicate that CD141hi DCs are capable of migration
to LNs in vivo, at least in the inflammatory setting of dermatosis
(Figures 4B and 4C).
CD141hi DCs Are Superior at Cross-Presentation of
Soluble Antigen
Having identified CD141hi DCs as a small subset of tissue-
derived DCs with a phenotype consistent with cross-presenting(Dermis) or with digesting dermis (+Dermis) and
d and skin donors for ‘‘spiking’’ experiment and five
nt of DCs in S, G2, or M phase in blood and skin.
Mann-Whitney U test comparing skin CD141hi DCs
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Figure 5. CD141hi DCs Are Superior at Cross-Presenting Soluble Antigen
(A and B) IFN-g production assessed by ELISpot assay upon cross-presentation of soluble HBsAg by blood and skin DCs to HLA-A*0201-restricted s183-91
CD8+ T cell clones at a DC:T cell ratio of 1:2.5. Composite data from four blood and seven skin donors are shown with mean ± SEM. *p < 0.05, Mann-Whitney
U test, comparing respective experimental condition for CD141+ blood and CD141hi skin DCs with CD1c+ DCs, CD14+ blood monocytes, skin DCs, and LCs.
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Immunity
Human Migratory Cross-Presenting CD141hi DCsDCs, we embarked on functional studies. We focused on
cells isolated from the skin, because it was more easily ob-
tained and contained the greatest number of cells. This still
presented a technical challenge, because the frequency of
CD141hi DCs is only 1% of CD45+ cells, or fewer than 500 cells
per cm2.
We tested the cross-presentation ability of CD141hi DCs,
CD1c+ DCs, CD14+ cells, and epidermal Langerhans cells from
the skin in comparison to CD141+ DCs, CD1c+ DCs, CD14+
monocytes, and in vitro monocyte-derived DCs (mo-DCs) and
monocyte-derived LCs (mo-LCs) obtained from blood. Cross-
presentation of hepatitis B surface antigen (HBsAg) to HLA-
A*0201-restricted s183-91-specific CD8+ T cell clones was
measured via an IFN-g ELISpot, as described in the Experi-
mental Procedures (Figures 5A and 5B). In blood, only CD141+
DCs were able to cross-present efficiently and required TLR3
stimulation with poly(I:C) or exposure to a maturation cocktail
(containing poly(I:C), LPS, IFN-g, IL-1b, TNF-a, and IFN-a).
Mature mo-DCs and mo-LCs were also able to cross-present
HBsAg upon exposure tomaturation cocktail but were refractory
to TLR3 stimulus alone (Figure 5A). In the skin, superior cross-
presenting capacity was found in CD141hi DCs, compared with
all other skin DC subsets, including LCs (Figure 5B). In keep-
ing with their more activated status, cross-presentation by
CD141hi DCs occurred in the absence of stimulation, although
TLR3 stimulation and maturation cocktail both increased this
activity. CD1c+ DCs showed little ability to cross-present
antigens, even when the CD141+ fraction of these cells was
specifically isolated and exposed to the maturation cocktail
(Figure 5B). Hypothesizing that CD1c+ and CD14+ DCs cross-
presenting capacities could be induced by other stimuli, we
exposed all DCs and LCs to a wide range of inflammatory
stimuli (including maturation cocktail plus GM-CSF, LPS plus
CD40 ligand, TLR8 agonist CL075, and mycobacterial extracts)
but none of these conditions elicited cross-presentation at a
greater level than with cytokine cocktail (Figure 5 and data not
shown). However, we cannot formally exclude that an untested
condition could enhance CD1c+ and CD14+ DCs cross-present-
ing capacities. The ability of CD141hi DCs to cross-present was
not a function of antigen uptake as indicated by the fact that
all populations were able to take up near-equivalent PE-labeled
HBsAg (Figure 5C).
CD141hi DCs were also the most active allostimulators of both
CD4+ and CD8+ T cells; CD14+ DCs showed the least activity
(Figure 5D). These results are consistent with the more activated
status of CD141hi DCs but did not indicate that they preferentially
stimulated CD8+ T cells, compared with other DCs.
CD141hi DCs Synthesize CXCL10 and TNF-a but Not
IL-12 or IL-23
Polarization of T cell responses by cytokine production is an
important function of DCs. In the mouse, cross-presentation to(C) Uptake of PE-labeled HBsAg and FITC-conjugated Dextran by skin CD141h
sentative data from two skin donors are shown; median fluorescent intensity of a
stated in the histogram box.
(D) Alloactivation of CD4+ and CD8+ T cells by skin CD141hi DCs (red), CD1c+ D
CFSE dilution. Representative dot plots and composite results from four skin d
correction.CD8+ T cells usually occurs in the context of a Th1 cell response
reinforced by IL-12 production (Reis e Sousa et al., 1997).
However, no interstitial DC subset produced IL-12p70 even
after stimulation, although IL-23p19 was synthesized in modest
amounts. Both were easily detected in cultures of mo-DCs
(Figure 6A). CD141hi DCs were most efficient at TNF-a and
CXCL10 production after TLR3 stimulation but produced very
little IL-1, IL-6, IL-8, or IL-10. LCs also produced CXCL10.
CD14+ DCs were the highest producers of IL-1, IL-6, and
IL-10 whereas CD1c+ DCs produced mainly IL-8 and IL-10 (Fig-
ure 6B). Neither CD1c+ DCs nor CD14+ DCs produced TNF-a
or CXCL10 in response to all inflammatory conditions tested
(Figure 6B) including LPS + CD40L, CL075, and mycobacterial
extract (data not shown).
Transcriptome Mapping of Human and Mouse
Nonlymphoid Tissue DCs
The alignment of DC subsets between mouse and human is of
key importance in correlating human studies with mouse in vivo
experiments (Guilliams et al., 2010). The results described above
suggest that CD141hi DCs are functional homologs of mouse
CD103+ DCs and that these are distinct from the major popula-
tion of human CD1c+ DCs and mouse CD11b+ DCs. We sought
to verify the conservation between species by an unbiased
approach. In order to strengthen the analysis, we included
human blood DCs and mouse lymphoid DCs.
We sorted tissueDC subsets, blood DCs, andmonocytes from
human samples and generated gene signatures for each subset
by removing tissue-specific expression patterns as detailed in
the Supplemental Experimental Procedures. Sorted populations
are shown in Table S1. A hierarchical clustering of all the subsets
used for signature generation shows close clustering of CD141hi
skin DCs with CD141+ blood DCs and CD1c+ DCs from blood
with CD1c+ DCs from skin, suggesting the existence of two
common DC subsets in blood and skin (Figure 7A).
Connectivity map analysis (CMAP) was performed comparing
the skin CD141hi DC gene set with the expression profile of other
human DC and monocyte subsets (full details of bioinformatics
analysis are described in Supplemental Experimental Proce-
dures). The CMAP scores are scaled dimensionless quantities
that indicate the degree of enrichment or ‘‘closeness’’ of one
DC subset to another. CD141+ blood DCs show the highest
enrichment with skin CD141hi DCs, followed by pDCs, then
CD1c DCs of skin and blood. CD14+ skin DCs and blood mono-
cyte subsets both show inverse relationships with skin CD141hi
DCs (Figure 7B). This analysis also indicates similar enrichment
scores between CD141+ and CD141 fractions of CD1c+ skin
cells, suggesting that they are both components of the CD1c
lineage.
Because skin CD141hi and blood CD141+ DCs and CD1c+
DCs from both skin and blood clustered with each other, we
generated a pooled skin CD141hi or blood CD141+ DC signaturei DCs (red), CD1c+ DCs (green), CD14+ DCs (blue), and LCs (purple). Repre-
ntigen uptake for each DC subset at 37C (color) compared to 4C (gray) are
Cs (green), and CD14+ DCs (blue). Proliferation was measured over 6 days by
onors are shown, mean ± SEM. *p < 0.05, ANOVA with post-test Bonferroni
Immunity 37, 60–73, July 27, 2012 ª2012 Elsevier Inc. 67
pg
/m
L
CXCL10 CD141hi
CD1c+
CD14+
-  pIC
 LPS  c  pIC LPS-
pg
/m
L
 pIC LPS-
IL-6
-  pIC LPS  c
pg
/m
L
IL-8
-  pIC LPS  c
p
g
/m
L
pg
/m
L
pg
/m
L
IL-10
IL-23p19
-  pIC LPS  c
IL-12p70
mo-DC
- pICLPS  c
pg
/m
L
pg
/m
L
c
c
N/A
-  pIC LPS   c
N/A
0
500
1000
1500
2000
c +GMCSF
*0
1000
2000
3000
****
0
100
200
300
400
500
 c +GMCSF
0
6000
12000
18000
c +GMCSF
* *
0
1000
2000
3000
4000
c +GMCSF
0
50
100
150
200
250
N/A
0
20
40
60
c +GMCSF
N/A
0
20
40
60
80
100
c +GMCSF
c +GMCSF
* *
**
LC
CD141hi
CD1c+
CD14+
LC
A
B
Figure 6. CD141hi DCs Synthesize CXCL10
and TNF-a but Not IL-12
(A) IL-12p70 and IL-23p19 production from un-
stimulated (), LPS (LPS)-, poly(I:C) (pIC)-, a
cocktail of TNF-a, IL-1b, IFN-a, IFN-g, LPS, and
pIC (c)-, and cocktail with the addition of GM-CSF
(c + GM-CSF)-stimulated CD141hi DCs, CD1c+
DCs, CD14+ DCs, and LCs with mo-DCs as
control. Composite results from six donors are
shown, mean ± SEM. Asterisk denotes subset not
analyzed.
(B) CXCL10, TNF-a, IL-1b, IL-6, IL-8, IL-10, IL-
23p19, and IL-12p70 production from CD141hi
DCs, CD1c+ DCs, CD14+ DCs, and LCs as stim-
ulated in (A). Composite results from four donors
are shown, mean ± SEM. Asterisk denotes subset
not analyzed.
Immunity
Human Migratory Cross-Presenting CD141hi DCsand a pooled CD1c+ DC signature from the two tissues. This
was used to interrogate the relationship between these two
human ‘‘DC lineages’’ and mouse DC subsets by further CMAP
analysis (Figure 7C). Corresponding sorted mouse populations
are shown in Table S1. The human CD141 lineage shared the
highest enrichment scores with mouse CD103+ tissue DCs and
CD8+ splenic DCs. In contrast, the CD1c lineage was closest
to mouse splenic CD11b+CD4+ DCs. CD11b+ DCs in murine
nonlymphoid tissues were more distantly related to the human
CD1c lineage. CD11b+ murine DCs from lung had a positive
association with human CD14+ DCs. This suggests that the
CD11b+ population is heterogeneous and contains mouse
equivalents of CD14+ DCs in a higher proportion in the lung
than the liver. In addition, CD14+ DCs from the skin generated
the highest enrichment with CD14+ monocytes and mouse
monocytes (Figure 7C). This analysis suggests by an unbiased
means that CD141hi skin DCs have a transcriptional profile that
links them to murine CD103+ tissue DCs and that both form
a conserved DC lineage that includes CD141+ blood DCs in
humans and CD8+ lymphoid DCs in mice.68 Immunity 37, 60–73, July 27, 2012 ª2012 Elsevier Inc.DISCUSSION
This study describes the phenotype and
function of a discrete human DC subset
identified by high CD141 and low-to-
intermediate CD11c expression, found
within the HLA-DR+lineageCD14 frac-
tion of leukocytes isolated from skin,
liver, and lung. CD141hi DCs express
CLEC9A, TLR3, CADM1, and XCR1 and
consequently migrate in response to
XCL1. Skin CD141hi DCs are proliferating
and include a subset of immature cells
related to but distinct from blood
CD141+ DCs, suggesting that they are
potentially derived from CD141+ blood
DCs. CD141hi DCs acquire CD1c and
CD1a, markers that are also expressed
when human CD34+ progenitor cells or
monocytes differentiate into DCs in vitro(Albert et al., 1998; Klechevsky et al., 2008). CD141hi DCs in
skin also express CCR7, migrate spontaneously, and are detect-
able as a distinct population within the migratory fraction of DCs
in skin-draining lymph nodes. In vitro, CD141hi DCs are most
efficient at cross-presenting soluble antigens compared with
other interstitial DCs and epidermal LCs. A wide range
of inflammatory stimuli were tested, including TNF-a, IFN-a,
GM-CSF, and LPS, with CD40 ligand, but failed to elicit efficient
cross-presentation by other interstitial DCs or LCs. Monocyte-
derived DCs and LCs were both able to cross-present in the
assay but less so than CD141hi DCs. Published data show that
CD34-derived langerin+ DCs are good at cross-presentation
compared with CD14+ DCs (Klechevsky et al., 2008). This
contrasts with another report showing poor cross-presenting
function of primary epidermal LCs (van der Vlist et al., 2011).
Our data reconcile these observations to some degree showing
that in-vitro-derived LCs have superior cross-presenting ability
compared with primary LCs.
CD141hi DCs synthesize very little IL-12 and IL-23 when
stimulated but produce CXCL10 and TNF-a. No stimuli elicited
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Figure 7. TranscriptomeMapping of Human
and Mouse Nonlymphoid Tissue DCs
Microarray expression profiles were obtained from
FACS-purified monocyte and DC subsets from
human blood and skin and mouse bone marrow,
blood, spleen, liver, and lung.
(A) Cluster dendrogram of human DC and mono-
cyte subsets after removal of tissue-specific genes
demonstrating the relationships between blood
CD141+ DCs and skin CD141hi DCs (red), blood
and skin CD1c+ DCs (green), CD14+ monocytes
and DCs (blue), blood CD16+ monocytes (light
blue), and pDCs (brown). Microarray profiles were
obtained from six blood and four skin donors.
(B) CMAP enrichment scores for skin CD141hi
DCs against all human skin and blood monocyte
and DC subsets. Scatterplot and mean, a 1,000
permutation test between gene signatures was
performed on each enrichment score to determine
significance. Enrichment scores for human skin
CD141hi DCs with all other human monocyte and
DC subsets were significant at p < 0.0001.
(C) CMAP enrichment scores for human (1) CD141
lineage, (2) CD1c lineage, (3) skin CD14+ DCs,
and (4) blood CD14+ monocytes against mouse
monocyte and DC subsets. CMAP analysis was
performed with mouse orthologs of human tran-
scripts. Microarray profiles were obtained from
3–4 experimental sets from 10–15 WT mice per
set. Scatterplot and mean, a 1,000 permutation
test between gene signatures was performed on
each enrichment score to determine significance.
Enrichment scores were significant at p < 0.05 for
all data sets except for the inverse association
between human CD1c lineage with mouse Gr1hi
and Gr1lo monocytes.
Immunity
Human Migratory Cross-Presenting CD141hi DCsCXCL10 or TNF-a from CD1c+ and CD14+ DCs. We considered
the possibility that inflammatory cytokine production might be
required for cross-presentation by these cells, but the addition
of exogenous TNF-a, IFN-a, and GM-CSF failed to confer
cross-presenting capacity. LCs produced CXCL10 but did not
cross-present efficiently. It remains a formal possibility that
an untested condition will induce cross-presenting capacity in
CD1c+ and CD14+ DCs, but we did not find this among a wide
range of physiological stimuli.
The production of CXCL10 by CD141hi DCs is interesting
because XCL1 and CXCL10 potentially form a chemokine circuit
between DCs bearing XCR1 and activated NK cells or Th1 cells
(Dorner et al., 2009; Crozat et al., 2010a; Contreras et al., 2010).
These lymphocytes express the CXCL10 receptor CXCR3Immunity 37, 6(Acosta-Rodriguez et al., 2007) and are
also major producers of XCL1.
In addition to CD141hi DCs, human
tissues contain CD1c+ DCs and CD14+
DCs, as previously described, notably in
the skin (Lenz et al., 1993; Nestle et al.,
1993; Haniffa et al., 2009). CD141hi
DCs were more difficult to isolate than
CD141+ blood DCs, owing to the upregu-
lation of CD141 on a number of other cells
including CD14+ DCs and a proportion ofCD1c+ DCs. Although CD141 is not selectively expressed, this
antigen can be used to identify cross-presenting tissue DCs
in the appropriate context. Other markers such as CLEC9A
and XCR1 are highly discriminatory, as emphasized by others
(Caminschi et al., 2008; Huysamen et al., 2008; Sancho et al.,
2009; Crozat et al., 2011), but are difficult to stain on tissue cells.
To validate the identity of CD141hi DCs, we showed that other
CD141-expressing cells lacked the critical features of cross-pre-
senting DCs in phenotypic and functional assays.
A recent study isolated CD141+ DCs from human skin that also
express CD14, produce IL-10, and induce regulatory T cells
(Chu et al., 2012). This population most probably corresponds
to ‘‘CD14+ DCs,’’ which we noted to express CD141 and
synthesize IL-10. In contrast to Chu et al. (2012), we did not0–73, July 27, 2012 ª2012 Elsevier Inc. 69
Immunity
Human Migratory Cross-Presenting CD141hi DCsfind CD14+ DCs efficient at cross-presentation. Our transcrip-
tomic analysis indicates that CD14+ DCs are related to blood
monocytes rather than the cross-presenting DCs of mouse
tissues and human blood. Notably, Chu et al. (2012) also demon-
strate that equivalents of their skin CD14+CD141+ DCs can be
derived from human monocytes.
Having isolated CD141hi DCs from skin, liver, and lung, we also
demonstrated migratory and resident CD141hi populations in
skin-draining lymph nodes. Cells bearing related markers have
previously been reported in the T cell areas of lymphoid tissues,
bone marrow (Jongbloed et al., 2010), and in the spleen (Galibert
et al., 2005; Poulin et al., 2010; Mittag et al., 2011). With the
exception of splenic DCs, functional studies were not under-
taken with these lymphoid-derived populations (Galibert et al.,
2005). Work with humanized mice has also described the
development of CD141+ DCs similar to blood CD141+ DCs in
the spleen but not in nonlymphoid organs (Poulin et al., 2010).
CD141+ cells have been found in human lung, alveolar fluid,
and kidneys but have not been characterized in detail (Demedts
et al., 2005; Tsoumakidou et al., 2006; Fiore et al., 2008). A
recent report characterizing migratory and resident DCs from
human lymph nodes concluded that CLEC9A+ DCs were absent
among migratory skin DCs (Segura et al., 2012). In this study,
CD1aCD14 DCs were examined for CLEC9A expression.
We have shown that skin migratory CD141hi DCs coexpress
CLEC9A but most are also positive for CD1a. It is therefore
possible that CLEC9A+ migratory DCs are excluded by gating
only CD1a-negative cells.
Functional alignment of human and mouse DC subsets has
been hampered by differences in surface marker expression
and accessibility of equivalent sources. The identification of
cross-presenting DCs as a specialized lineage first in mouse
and now in humans has been predicated on a small number of
specialized markers including NECL2 (cellular adhesion mole-
cule-1; CADM1) (Galibert et al., 2005), CLEC9A (Caminschi
et al., 2008; Huysamen et al., 2008; Sancho et al., 2009), XCR1
(Dorner et al., 2009; Crozat et al., 2010a), and TLR3. These anal-
yses focused on human blood but did not address nonlymphoid
organs. In the tissues, neither CD1c+ nor CD14+ DCs excel at
cross-presentation and the CD14+ subset shares features of
monocytes or macrophages (Haniffa et al., 2009) making it diffi-
cult to envisage comparisons with mouse CD103+ and CD11b+
DCs. The identification of CD141hi DCs therefore provided a
missing link with which to compare human and mouse DC
subsets of nonlymphoid origin and to explore the wider relation-
ships between the species.
For this purpose, we developed a modification of the func-
tional genomic analysis by gene set enrichment analysis
(GSEA), pioneered by Dalod and colleagues (Robbins et al.,
2008; Crozat et al., 2010b, 2011). By eliminating probe sets
that were differentially expressed between skin and blood, we
were able to derive subset-specific signature transcriptomes
that were not defined by arbitrary expression level thresholds.
In order to compare these signatures, we adapted CMAP, an
extension of the GSEA algorithm (Lamb et al., 2006). This gives
enrichment scores with a directional element assigning positive
and negative scores to proximal and distal relationships, respec-
tively. The enrichment scores obtained from CMAP analysis
suggests the existence of at least three separate antigen-70 Immunity 37, 60–73, July 27, 2012 ª2012 Elsevier Inc.presenting lineages conserved across species: (1) CD141hi or
CD141+ cross-presenting DCs linked with mouse CD103+ or
CD8+ DCs; (2) CD1c+ ‘‘myeloid’’ DCs linked with mouse splenic
CD4+ DCs; and (3) CD14+ monocyte-associated or monocyte-
derived DCs linked with mouse monocytes and also more
distantly with mouse CD11b+ DCs. These data not only validate
the CD141hi DCs as the cross-presenting DCs of human tissues
by an unbiased means but also align the entire human and
mouse nonlymphoid DC subsets.
A few exceptions are notable between mouse and human
cross-presenting subsets. CD141hi DCs and blood CD141+
DCs produce very little IL-12 (Jongbloed et al., 2010; Poulin
et al., 2010) in contrast to monocyte-derived DCs (Ebner et al.,
2001) and mouse cross-presenting DCs (Reis e Sousa et al.,
1997). In addition, human CD141hi DCs do not express langerin
that characterizes mouse CD8+ or CD103+ DCs in many tissues,
notably the skin (Ginhoux et al., 2009). Rather, our data indicate
that langerin is more likely to be found on the CD1c+ population,
especially in liver and lung (Eisenwort et al., 2011; V.B., data not
shown).
The finding that human CD14+ DCs are linked to monocyte
populations in both mouse and human is intriguing and consis-
tent with our initial observation that CD14+ DCs express
M-CSFR and CX3CR1 but very little FLT3. They also express
CD209 (DC-SIGN) in common with mo-DCs and have been
found to be poor allostimulators in vitro (Klechevsky et al.,
2008; Haniffa et al., 2009). There is no homolog of CD14+ DCs
in mouse tissues but we speculate that the mouse CD11b+ DC
fraction of nonlymphoid tissue is heterogeneous, comprising
equivalents of both CD1c+ DCs and CD14+ DCs. This potentially
explains the intermediate relationship of mouse CD11b+ DCs
with respect to CD1c+ and CD14+ DCs by CMAP analysis.
CD11b+ mouse spleen DCs was recently shown to be heteroge-
neous containing CD4+ and CD4 fractions, the latter being
monocyte derived (Lewis et al., 2011; Kasahara and Clark,
2012). Consistent with this, we noted that CD4+ splenic DCs
were much more closely linked to CD1c+ DCs than were
CD11b+ DCs from tissues, which by analogy probably contain
a monocyte-derived component. Altogether, our comparison
of human andmouse DC subsets aligns the functional classifica-
tion of DCs across species and allows clear inferences to be
drawn between mouse and human.
Targeting lectins associated with specific DC subsets is
feasible in mice (Bonifaz et al., 2004; Dudziak et al., 2007),
primates, and humans (Flynn et al., 2011; Tsuji et al., 2011).
We anticipate that the identification of CD141hi DCs will facilitate
future rational vaccine design.EXPERIMENTAL PROCEDURES
Cell Isolation and Culture
Human samples were obtained in accordance with a favorable ethical opinion
from Newcastle and Singapore Singhealth and National Health Care Group
Research Ethics Committees.
Normal skin was obtained from mammoplasty and breast reconstruction
surgery. Lung and liver were obtained from peritumoral tissue. Tonsil and der-
matopathic lymph nodes were obtained from tonsillectomy and lymph node
diagnostic excisions. 300 mm whole skin dermatome sections, liver, and lung
were cut into 0.5 cm squares and incubated with 0.8 mg/ml collagenase
(Type IV, Worthington-Biochemical) in RPMI (PAA) with 10% FCS
Immunity
Human Migratory Cross-Presenting CD141hi DCs(AutogenBioclear) for 2 and 8 hr, respectively, or where stated mechanically
dispersed. For LC isolation, skin was incubated in 1mg/ml dispase (Invitrogen)
for 1 hr to separate epidermis from dermis prior to collagenase treatment.
Migrating cells were collected from whole skin cultured in RPMI with 10%
FCS with or without 1 mg/ml XCL1 (R&D) or 0.1 mg/ml CCL3 (R&D). Viability
was >90% by DAPI exclusion (Sigma).
Peripheral blood mononuclear cells were isolated by density centrifugation
(Ficoll-Paque; GE Healthcare). CD3+ T cells were isolated from whole blood
to >95% purity with Rosette-Sep isolation kit (StemCell Technologies). HLA-
A*0201 hepatitis B surface antigen 183-91 (HBs183-91)-restricted CD8+
T cell clones were generated as previously described (Gehring et al., 2011).
Blood, lung, liver, and dermal DC subsets and epidermal LCs were isolated
to >91% purity by fluorescence activated cell sorting (FACS) with a FACSAriaII
(Becton Dickinson [BD]). Monocyte-derived DCs (mo-DCs) were generated
from magnetically isolated CD14+ monocytes (Miltenyi Biotec) cultured for
6 days with 50 ng/ml rGM-CSF and IL-4 (R&D).Flow Cytometry
Flow cytometry was performed on a BDLSRII and FACSCanto and data
analyzed with FlowJo (Treestar). FITC-coated dextran particles (MW70,000)
were obtained from Sigma. Antibodies used are listed in Supplemental Exper-
imental Procedures.
For determination of DNA ploidy, FACS-sorted cells were fixed, permeabi-
lized with BD Cytofix, Cytoperm, and Permwash, treated with 70% ice-cold
ethanol for 2 hr, washed, and resuspended in 2 mg/ml DAPI solution.Microscopy
200 mm skin sheet was fixed in PBS containing 2% paraformaldehyde and
30% sucrose overnight at 4C. Skin was incubated overnight in PBS contain-
ing 0.5% BSA and 0.3% Triton X-100 before staining with the following
primary and secondary antibodies at 4C overnight at each stage: XCR1
(polyclonal, LSBio), CD11c (B-ly6, BD Biosciences), HLA-DR FITC (L243,
BD Biosciences), HLA-DQ FITC (SK10, BD Biosciences), and HLA-DP FITC
(HI43, BioLegend); and donkey anti-rabbit and donkey anti-mouse Dy549
or Dy649 (Jackson ImmunoResearch) and donkey anti-sheep Alexa Fluor
647 (Invitrogen). Specimens were viewed with Axio Imager.Z2 fluorescence
microscope with Axiovision software v4.8 and Axiocam MR3 camera (Carl
Zeiss, Inc.).
Cytospins were prepared from FACS-purified DCs and stained with the
Hema 3 System according to manufacturer’s protocol (Fisher Diagnostics).
Images were analyzed with a Nikon Eclipse E800 microscope (Nikon). For
scanning electron microscopy (SEM), sorted cells coated on poly-lysine
(Sigma) glass coverslips were fixed in 2.5% glutaraldehyde, washed, treated
with 1% osmium tetroxide (Ted Pella Inc.), and critical point dried (CPD 030,
Bal-Tec). Glass coverslips were sputter-coated with platinum in a high-
vacuum sputtering device (SCD005 sputter coater, Bal-Tec) and imaged
with a field emission scanning electron microscope (JSM-6701F, JEOL) at
an acceleration voltage of 8 kV.Dermal APC Stimulation with TLR Ligands
FACS-purified dermal DCs were cultured in 96-well V-bottomed plates.
Supernatant from unstimulated and cells stimulated with 0.1 mg/ml LPS
(Sigma), 10 mg/ml poly(I:C) (InvivoGen), a ‘‘cocktail’’ containing 0.1 mg/ml
LPS, 25 mg/ml poly(I:C), 1,000 IU/ml IFN-g (R&D), 50 ng/ml TNF-a (R&D),
3,000 IU/ml IFN-a (R&D), and 25 ng/ml IL-1b (R&D) with and without
50 ng/ml GM-CSF, 1 mg/ml of the TLR8 agonist CL075 (InvivoGen), and
20 mg/ml mycobacterial extracts (Strain H37Rv; BEI Resources) were
collected after 24 hr for cytokine analysis. TNF-a, IL-1b, IL-6, IL-10, IL-
12p70, and CXCL10 were detected with BD Cytometric Bead Arrays and
analyzed with BD-FCAP Array software v1.0. IL-23p19 was measured by
ELISA (R&D Quantikine ELISA kit).Proliferation and T Cell Cytokine Production Assays
5,000 flow-sorted dermal DC subsets were cultured with 100,000 allogeneic
CFSE-labeled CD3+ T cells in U-bottomed 96-well plates. Proliferation was
assessed by CFSE dilution on day 6.Cross-Presentation and ELISpot Assay
4,000 FACS-sorted blood and dermal DCs or mo-DCs from HLA-A2+ donors
were pulsed with 10 mg/ml Hepatitis B surface antigen (HBsAg) (Rhein Biotech)
with and without poly(I:C) (25 mg/ml) and a cocktail (as stated above) over-
night in RPMI with 10% FCS. DCs were pulsed with HBs183-91 peptide
(FLLTRILTI) for 3 hr. DCs were washed extensively and cultured with HLA-
A*0201 HBs183-91-restricted CD8+ T cell clones in RPMI with 10% FCS and
IFN-g production assessed after 18 hr by ELISpot. IFN-g spots were detected
with an IFN-g antibody kit (Mabtech) and counted with CTL ImmunoSpot
S5 UV Analyzer and ImmunoSpot Version 5 Professional Software.
Quantitative Real-Time PCR
RNA was extracted with the RNeasy Micro Kit (QIAGEN) and reverse tran-
scribed into cDNA by oligo-dT primer (Invitrogen) and Superscript First Strand
Synthesis System (Invitrogen). cDNA was analyzed by real-time PCR with
SYBR Green I Master Mix (Roche) with the LightCycler 480 System (Roche)
for the following genes:GAPDH, XCR1, TLR3, and CADM1 (primer sequences
are listed in Supplemental Experimental Procedures).
Details of transcriptomic analysis are available in Supplemental Experi-
mental Procedures.
Statistical Analyses
All statistical analyses were performed with Prism 5.0 (GraphPad Software).
All p values are two-tailed.
ACCESSION NUMBERS
The microarray data are available in the Gene Expression Omnibus (GEO)
database (http://www.ncbi.nlm.nih.gov/gds) under the accession number
GSE35459.
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